James Caruso | executive |
Chad Kolean | executive |
Darrell Lea | executive |
Jarrod Longcor | executive |
Ahu Demir | analyst |
Jeffrey Jones | analyst |
Andrei Shustov | executive |
Jonathan Aschoff | analyst |
Good morning, and welcome to Cellectar Biosciences 2024 Year-End (sic) [ First Quarter ] Earnings Call. Today's call is being recorded.
Before we begin, I would like to remind everyone that statements made during this call relating to Cellectar's expected future performance, future business prospects or future events or plans are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995.
Although the company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, actual outcomes and results are subject to risks and uncertainties that could differ materially from those forecast due to the impact of many factors beyond the company -- the control of Cellectar.
The company assumes no obligation to update or supplement any forward-looking statements, whether as a result of new information, future events or otherwise.